Research14 min
FORZINITY (Elamipretide/SS-31): The First FDA-Approved Mitochondrial Peptide — And What It Signals for the Field
In September 2025, the FDA quietly approved the first mitochondria-targeted peptide therapeutic in history. The drug is FORZINITY — the commercial form of SS-31, a peptide that's been studied in everything from heart failure to age-related macular degeneration to aged-muscle frailty. Here's what the approval actually says, what the trials really showed, and why this is bigger than Barth syndrome.
Anti-Aging & Longevity